The Efficacy and Safety of UGN-102 as a Chemical Ablation Agent in Patients With LG NMIBC at Intermediate Risk of Recurrence

Conditions:   Bladder Cancer;   Urothelial Carcinoma;   Urothelial Carcinoma Bladder
Intervention:   Drug: UGN-102
Sponsor:   UroGen Pharma Ltd.
Not yet recruiting

https://ift.tt/2MvNt4H